1
|
Coconut endocarp shell ash (CESA): a versatile and waste-originated catalyst for the synthesis of tetrahydrobenzo[b]pyrans and 1, 4-dihydropyridines. RESEARCH ON CHEMICAL INTERMEDIATES 2022. [DOI: 10.1007/s11164-022-04770-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
2
|
Dakhlaoui I, Maalej E, Martin H, Lucht A, Iriepa I, Moraleda I, Marco‐Contelles J, Chabchoub F, Ismaili L. Synthesis and Biological Assessment of PyrimidoTacrines as Promising Agents for Alzheimer's Disease Therapy. ChemistrySelect 2021. [DOI: 10.1002/slct.202102363] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Imen Dakhlaoui
- Laboratoire de Chimie Appliquée: Hétérocycles Corps Gras et Polymères Faculté des Sciences de Sfax Université de Sfax. B. P 802.3000 Sfax Tunisie
- UR Neurosciences Medicinal chemistry group Univ. Bourgogne Franche-Comté, UFR Santé 19, rue Ambroise Paré F-25000 Besançon France
| | - Emna Maalej
- Laboratoire Matériaux Traitement et Analyse (LMTA) Institut National de Recherche et d'Analyse Physico-chimique Technopole Ariana Tunisia
| | - Helene Martin
- PEPITE EA4267 Laboratoire de Toxicologie Cellulaire Univ. Bourgogne Franche-Comté F-25000 Besançon France
| | - Aurélia Lucht
- UR Neurosciences Medicinal chemistry group Univ. Bourgogne Franche-Comté, UFR Santé 19, rue Ambroise Paré F-25000 Besançon France
| | - Isabel Iriepa
- Organic and Inorganic Chemistry Department. Ctra. Madrid-Barcelona, Km. 33, 6 University of Alcala 28871 Madrid Spain
| | - Ignacio Moraleda
- Organic and Inorganic Chemistry Department. Ctra. Madrid-Barcelona, Km. 33, 6 University of Alcala 28871 Madrid Spain
| | - Jose Marco‐Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC) Juan de la Cierva, 3 28006 Madrid Spain
| | - Fakher Chabchoub
- Laboratoire de Chimie Appliquée: Hétérocycles Corps Gras et Polymères Faculté des Sciences de Sfax Université de Sfax. B. P 802.3000 Sfax Tunisie
| | - Lhassane Ismaili
- UR Neurosciences Medicinal chemistry group Univ. Bourgogne Franche-Comté, UFR Santé 19, rue Ambroise Paré F-25000 Besançon France
| |
Collapse
|
3
|
Dakhlaoui I, Vahdati S, Maalej E, Chabchoub F, Wiese M, Marco-Contelles J, Ismaili L. Synthesis and biological assessment of new pyrimidopyrimidines as inhibitors of breast cancer resistance protein (ABCG2). Bioorg Chem 2021; 116:105326. [PMID: 34536930 DOI: 10.1016/j.bioorg.2021.105326] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Revised: 08/29/2021] [Accepted: 08/30/2021] [Indexed: 11/26/2022]
Abstract
Multidrug resistance constitutes a serious obstacle of the treatment success of cancer by chemotherapy. Mostly it is driven by expression of ABC transport proteins that actively efflux the anticancer agents out of the cell. This work describes the design and synthesis of 12 new pyrimidopyrimidines, as well as their inhibition of ABCG2 a transporter referred also to as breast cancer resistance protein, the selectivity versus ABCB1 (P-glycoprotein/P-gp) and ABCC1 as well as the investigation of their accumulation in single cells. From these results, N-(3,5-dimethoxyphenyl)-2-methyl-7-phenyl-5-(p-tolyl)pyrimido[4,5-d]pyrimidin-4-amine 7 h was identified as promising hit that deserves further investigation showing a selective and effective inhibition of ABCG2 with IC50 equal to 0.493 µM only 2-fold less active than Ko143.
Collapse
Affiliation(s)
- Imen Dakhlaoui
- Laboratoire de Chimie Appliquée: Hetérocycles, Corps Gras et Polymères, Faculté des Sciences de Sfax, Université de Sfax, B. P 802, 3000 Sfax, Tunisia; Laboratoire de Chimie Organique et Thérapeutique, Neurosciences intégratives et cliniques EA 481, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France
| | - Sahel Vahdati
- Pharmaceutical Institute, University of Bonn, An der Immenburg 4 53121, Bonn, Germany
| | - Emna Maalej
- Laboratoire de Chimie Appliquée: Hetérocycles, Corps Gras et Polymères, Faculté des Sciences de Sfax, Université de Sfax, B. P 802, 3000 Sfax, Tunisia; Laboratoire Matériaux, Traitement et Analyse (LMTA), Institut National de Recherche et d'Analyse Physico-chimique Technopole, Ariana, Tunisia
| | - Fakher Chabchoub
- Laboratoire de Chimie Appliquée: Hetérocycles, Corps Gras et Polymères, Faculté des Sciences de Sfax, Université de Sfax, B. P 802, 3000 Sfax, Tunisia.
| | - Michael Wiese
- Pharmaceutical Institute, University of Bonn, An der Immenburg 4 53121, Bonn, Germany.
| | - Jose Marco-Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC), Juan de la Cierva, 3, 28006 Madrid, Spain
| | - Lhassane Ismaili
- Laboratoire de Chimie Organique et Thérapeutique, Neurosciences intégratives et cliniques EA 481, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France.
| |
Collapse
|
4
|
Purgatorio R, de Candia M, Catto M, Rullo M, Pisani L, Denora N, Carrieri A, Nevskaya AA, Voskressensky LG, Altomare CD. Evaluation of Water-Soluble Mannich Base Prodrugs of 2,3,4,5-Tetrahydroazepino[4,3-b]indol-1(6H)-one as Multitarget-Directed Agents for Alzheimer's Disease. ChemMedChem 2020; 16:589-598. [PMID: 33156950 DOI: 10.1002/cmdc.202000583] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2020] [Revised: 10/17/2020] [Indexed: 12/19/2022]
Abstract
Different Mannich base derivatives have been studied with the aim of addressing the poor aqueous solubility of the recently disclosed 6-phenethyl-2,3,4,5-tetrahydroazepino[4,3-b]indol-1(6H)-one (1), a human butyrylcholinesterase inhibitor (hBChE, IC50 13 nM) and protective agent in NMDA-induced neurotoxicity, in in vivo assays. The N-(4-methylpiperazin-1-yl)methyl derivative 2 c showed a 50-fold increase in solubility in pH 7.4-buffered solution, high stability in serum and (half-life >24 h) and rapid (<3 min) conversion to 1 at acidic pH. Although less active than 1, 2 c retained moderate hBChE inhibition (IC50 =3.35 μM) and a significant protective effect against NMDA-induced neurotoxicity at 0.1 μM. Moreover, 2 c resulted a weaker serum albumin binder than 1, could pass the blood-brain barrier, and exerted negligible cytotoxicity on HepG2 cells. These findings suggest that 2 c could be a water-soluble prodrug candidate of 1 for oral administration or a slow-release injectable derivative in in vivoAlzheimer's disease models.
Collapse
Affiliation(s)
- Rosa Purgatorio
- Department of Pharmacy-Drug-Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Modesto de Candia
- Department of Pharmacy-Drug-Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Marco Catto
- Department of Pharmacy-Drug-Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Mariagrazia Rullo
- Department of Pharmacy-Drug-Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Leonardo Pisani
- Department of Pharmacy-Drug-Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Nunzio Denora
- Department of Pharmacy-Drug-Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Antonio Carrieri
- Department of Pharmacy-Drug-Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Alisa A Nevskaya
- Organic Chemistry Department, RUDN University, Miklukho-Maklai St. 6, Moscow, 117198, Russia
| | - Leonid G Voskressensky
- Organic Chemistry Department, RUDN University, Miklukho-Maklai St. 6, Moscow, 117198, Russia
| | - Cosimo D Altomare
- Department of Pharmacy-Drug-Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| |
Collapse
|
5
|
Pachón Angona I, Martin H, Daniel S, Moraleda I, Bonet A, Wnorowski A, Maj M, Jozwiak K, Iriepa I, Refouvelet B, Marco-Contelles J, Ismaili L. Synthesis of Hantzsch Adducts as Cholinesterases and Calcium Flux inhibitors, Antioxidants and Neuroprotectives. Int J Mol Sci 2020; 21:ijms21207652. [PMID: 33081112 PMCID: PMC7589057 DOI: 10.3390/ijms21207652] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Revised: 10/09/2020] [Accepted: 10/14/2020] [Indexed: 01/22/2023] Open
Abstract
We report herein the design, synthesis, biological evaluation, and molecular modelling of new inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), able to block Ca+2 channels also showing antioxidant and neuroprotective activities. The new MTDL, dialkyl 2,6-dimethyl-4-(4-((5-aminoalkyl)oxy)phenyl)-1,4-dihydropyridine-3,5-dicarboxylate 3a-p, have been obtained via Hantzsch reaction from appropriate and commercially available precursors. Pertinent biological analysis has prompted us to identify MTDL 3h [dimethyl-4-(4-((5-(4-benzylpiperidin-1-yl)pentyl)oxy)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate] as an attractive inhibitor of AChE (1.8 μM) and BuChE (2 μM), Ca+2 channel antagonist (47.72% at 10 μM), and antioxidant (2.54 TE) agent, showing significant neuroprotection 28.68% and 38.29% against H2O2, and O/R, respectively, at 0.3 μM, thus being considered a hit-compound for further investigation in our search for anti-Alzheimer's disease agents.
Collapse
Affiliation(s)
- Irene Pachón Angona
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France; (I.P.A.); (S.D.)
| | - Helene Martin
- PEPITE EA4267, Laboratoire de Toxicologie Cellulaire, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France; (H.M.); (A.B.)
| | - Solene Daniel
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France; (I.P.A.); (S.D.)
| | - Ignacio Moraleda
- Department of Organic Chemistry and Inorganic Chemistry, School Sciences, University of Alcalá, Ctra. Barcelona, Km. 33.6, 28871 Alcalá de Henares, Spain;
| | - Alexandre Bonet
- PEPITE EA4267, Laboratoire de Toxicologie Cellulaire, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France; (H.M.); (A.B.)
| | - Artur Wnorowski
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland; (A.W.); (M.M.); (K.J.)
| | - Maciej Maj
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland; (A.W.); (M.M.); (K.J.)
| | - Krzysztof Jozwiak
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland; (A.W.); (M.M.); (K.J.)
| | - Isabel Iriepa
- Department of Organic Chemistry and Inorganic Chemistry, School Sciences, University of Alcalá, Ctra. Barcelona, Km. 33.6, 28871 Alcalá de Henares, Spain;
- Correspondence: (I.I.); (B.R.); (L.I.)
| | - Bernard Refouvelet
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France; (I.P.A.); (S.D.)
- Correspondence: (I.I.); (B.R.); (L.I.)
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC), Juan de la Cierva, 3, 28006-Madrid, Spain;
| | - Lhassane Ismaili
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France; (I.P.A.); (S.D.)
- Correspondence: (I.I.); (B.R.); (L.I.)
| |
Collapse
|
6
|
Merged Tacrine-Based, Multitarget-Directed Acetylcholinesterase Inhibitors 2015-Present: Synthesis and Biological Activity. Int J Mol Sci 2020; 21:ijms21175965. [PMID: 32825138 PMCID: PMC7504404 DOI: 10.3390/ijms21175965] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 08/15/2020] [Accepted: 08/17/2020] [Indexed: 11/17/2022] Open
Abstract
Acetylcholinesterase is an important biochemical enzyme in that it controls acetylcholine-mediated neuronal transmission in the central nervous system, contains a unique structure with two binding sites connected by a gorge region, and it has historically been the main pharmacological target for treatment of Alzheimer's disease. Given the large projected increase in Alzheimer's disease cases in the coming decades and its complex, multifactorial nature, new drugs that target multiple aspects of the disease at once are needed. Tacrine, the first acetylcholinesterase inhibitor used clinically but withdrawn due to hepatotoxicity concerns, remains an important starting point in research for the development of multitarget-directed acetylcholinesterase inhibitors. This review highlights tacrine-based, multitarget-directed acetylcholinesterase inhibitors published in the literature since 2015 with a specific focus on merged compounds (i.e., compounds where tacrine and a second pharmacophore show significant overlap in structure). The synthesis of these compounds from readily available starting materials is discussed, along with acetylcholinesterase inhibition data, relative to tacrine, and structure activity relationships. Where applicable, molecular modeling, to elucidate key enzyme-inhibitor interactions, and secondary biological activity is highlighted. Of the numerous compounds identified, there is a subset with promising preliminary screening results, which should inspire further development and future research in this field.
Collapse
|
7
|
Triazolopyridopyrimidine: A New Scaffold for Dual-Target Small Molecules for Alzheimer's Disease Therapy. Molecules 2020; 25:molecules25143190. [PMID: 32668671 PMCID: PMC7397274 DOI: 10.3390/molecules25143190] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Revised: 07/09/2020] [Accepted: 07/12/2020] [Indexed: 12/02/2022] Open
Abstract
Alzheimer’s disease (AD) is multifactorial disease characterized by the accumulation of abnormal extracellular deposits of amyloid-beta (Aβ) peptide, and intracellular neurofibrillary tangles (NFTs), along with dramatic neuronal death and decreased levels of choline acetyltransferase. Given the limited therapeutic success of available drugs, it is urgent to explore all the opportunities available to combat this illness. Among them, the discovery of new heterocyclic scaffolds binding different receptors involved in AD should offer structural diversity and new therapeutic solutions. In this context, this work describes new triazolopyridopyrimidine easily prepared in good yields showing anticholinesterase inhibition and strong antioxidant power, particularly the most balanced: 6-amino-5-(4-methoxyphenyl)-2-phenyl-[1,2,4]triazolo[1′,5′:1,6] pyrido[2,3-d]pyrimidine-4-carbonitrile(3c) with IC50 equal to 1.32 μM against AChE and oxygen radical absorbance capacity (ORAC) value equal to 4.01 Trolox equivalents (TE); thus representing a new and very promising hit-triazolopyridopyrimidine for AD therapy.
Collapse
|
8
|
Mkaouar K, Iriepa I, Diez‐Iriepa D, Marco‐Contelles J, Ismaili L, Chabchoub F. Synthesis of (±)‐
cis
‐1‐Aryl‐3‐oxo‐2,3‐dihydro‐1
H
‐benzo[
f
]chromene‐2‐carbonitriles and (±)‐
trans
‐4‐Aryl‐2‐oxo‐3,4‐dihydro‐2
H
‐benzo[
h
]chromene‐3‐carbonitriles. ChemistrySelect 2019. [DOI: 10.1002/slct.201903982] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Kamar Mkaouar
- Laboratoire de Chimie Appliquée: HétérocyclesCorps Gras et Polymères, Faculté des Sciences de SfaxUniversité de Sfax. B. P 802. 3000 Sfax- Tunisie
- Laboratoire de Chimie Organique et ThérapeutiqueNeurosciences intégratives et cliniques EA 481Univ. Bourgogne Franche-Comté, UFR Santé 19, rue Ambroise Paré F-25000 Besançon France
| | - Isabel Iriepa
- Departamento de Química Orgánica and Química Inorgánica. Ctra. Madrid-BarcelonaUniversidad de Alcalá, Km. 33,6 28871 Madrid Spain
| | - Daniel Diez‐Iriepa
- Departamento de Química Orgánica and Química Inorgánica. Ctra. Madrid-BarcelonaUniversidad de Alcalá, Km. 33,6 28871 Madrid Spain
- Laboratory of Medicinal Chemistry (IQOG, CSIC) Juan de la Cierva, 3 28006- Madrid Spain
| | - José Marco‐Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC) Juan de la Cierva, 3 28006- Madrid Spain
| | - Lhassane Ismaili
- Laboratoire de Chimie Organique et ThérapeutiqueNeurosciences intégratives et cliniques EA 481Univ. Bourgogne Franche-Comté, UFR Santé 19, rue Ambroise Paré F-25000 Besançon France
| | - Fakher Chabchoub
- Laboratoire de Chimie Appliquée: HétérocyclesCorps Gras et Polymères, Faculté des Sciences de SfaxUniversité de Sfax. B. P 802. 3000 Sfax- Tunisie
| |
Collapse
|
9
|
Malek R, Arribas RL, Palomino-Antolin A, Totoson P, Demougeot C, Kobrlova T, Soukup O, Iriepa I, Moraleda I, Diez-Iriepa D, Godyń J, Panek D, Malawska B, Głuch-Lutwin M, Mordyl B, Siwek A, Chabchoub F, Marco-Contelles J, Kiec-Kononowicz K, Egea J, de los Ríos C, Ismaili L. New Dual Small Molecules for Alzheimer’s Disease Therapy Combining Histamine H3 Receptor (H3R) Antagonism and Calcium Channels Blockade with Additional Cholinesterase Inhibition. J Med Chem 2019; 62:11416-11422. [DOI: 10.1021/acs.jmedchem.9b00937] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Rim Malek
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Université Bourgogne Franche-Comté, UFR Santé, 19, Rue Ambroise Paré, F-25000 Besançon, France
- Laboratory of Applied Chemistry: Heterocycles, Lipids and Polymers, University of Sfax, B. P 802, 3000 Sfax, Tunisia
| | - Raquel L. Arribas
- Servicio de Farmacología Clínica, Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, C/Diego de León, 62, 28006 Madrid, Spain
- Instituto Teofilo Hernando, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029 Madrid, Spain
| | - Alejandra Palomino-Antolin
- Instituto Teofilo Hernando, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029 Madrid, Spain
- Molecular Neuroinflammation and Neuronal Plasticity Laboratory, Research Unit, Hospital Universitario Santa Cristina, 28009 Madrid, Spain
- Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, 28006 Madrid, Spain
| | - Perle Totoson
- EA4267 PEPITE, Université Bourgogne Franche-Comté, F-25030, Besançon, France
| | - Celine Demougeot
- EA4267 PEPITE, Université Bourgogne Franche-Comté, F-25030, Besançon, France
| | - Tereza Kobrlova
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, CZ-500 01 Hradec Kralove, Czech Republic
- Biomedical Research Center, University Hospital CZ-500 05 Hradec Kralove, Czech Republic
| | - Ondrej Soukup
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, CZ-500 01 Hradec Kralove, Czech Republic
- Biomedical Research Center, University Hospital CZ-500 05 Hradec Kralove, Czech Republic
| | | | | | - Daniel Diez-Iriepa
- Laboratory of Medicinal Chemistry, IQOG, CSIC, Juan de la Cierva 3, 28006 Madrid, Spain
| | - Justyna Godyń
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Dawid Panek
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Barbara Malawska
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Monika Głuch-Lutwin
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Barbara Mordyl
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Agata Siwek
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Fakher Chabchoub
- Laboratory of Applied Chemistry: Heterocycles, Lipids and Polymers, University of Sfax, B. P 802, 3000 Sfax, Tunisia
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry, IQOG, CSIC, Juan de la Cierva 3, 28006 Madrid, Spain
| | | | - Javier Egea
- Instituto Teofilo Hernando, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029 Madrid, Spain
- Molecular Neuroinflammation and Neuronal Plasticity Laboratory, Research Unit, Hospital Universitario Santa Cristina, 28009 Madrid, Spain
- Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, 28006 Madrid, Spain
| | - Cristóbal de los Ríos
- Servicio de Farmacología Clínica, Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, C/Diego de León, 62, 28006 Madrid, Spain
- Instituto Teofilo Hernando, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029 Madrid, Spain
| | - Lhassane Ismaili
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Université Bourgogne Franche-Comté, UFR Santé, 19, Rue Ambroise Paré, F-25000 Besançon, France
| |
Collapse
|
10
|
Dgachi Y, Martin H, Malek R, Jun D, Janockova J, Sepsova V, Soukup O, Iriepa I, Moraleda I, Maalej E, Carreiras MC, Refouvelet B, Chabchoub F, Marco-Contelles J, Ismaili L. Synthesis and biological assessment of KojoTacrines as new agents for Alzheimer's disease therapy. J Enzyme Inhib Med Chem 2019; 34:163-170. [PMID: 30482062 PMCID: PMC6263107 DOI: 10.1080/14756366.2018.1538136] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
In view of the multifactorial nature of Alzheimer’s disease (AD), multitarget small molecules (MTSM) represent the most potent and attractive therapeutic strategy to design new drugs for Alzheimer’s disease therapy. The new MTSM KojoTacrines (KTs) were designed and synthesized by juxtaposition of selected pharmacophoric motifs from kojic acid and tacrine. Among them, 11-amino-2-(hydroxymethyl)-12-(3-methoxyphenyl)-7,9,10,12-tetrahydropyrano [2',3':5,6] pyrano[2,3-b]quinolin-4(8H)-one (KT2d) was identified as less-hepatotoxic than tacrine, at higher concentration, a moderate, but selective human acetylcholinesterase inhibitor (IC50 = 4.52 ± 0.24 µM), as well as an antioxidant agent (TE = 4.79) showing significant neuroprotection against Aβ1–40 at 3 µM and 10 µM concentrations. Consequently, KT2d is a potential new hit-ligand for AD therapy for further biological exploration.
Collapse
Affiliation(s)
- Youssef Dgachi
- a Laboratory of Applied Chemistry, Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax , University of Sfax , Sfax , Tunisia.,b Laboratoire de Chimie Organique et Thérapeutique, Neurosciences Intégratives et Cliniques EA 481 , Univ. Bourgogne Franche-Comté , Besançon , France
| | - Hélène Martin
- c Laboratoire de Toxicologie Cellulaire , Univ. Bourgogne Franche-Comté , Besançon , France
| | - Rim Malek
- b Laboratoire de Chimie Organique et Thérapeutique, Neurosciences Intégratives et Cliniques EA 481 , Univ. Bourgogne Franche-Comté , Besançon , France
| | - Daniel Jun
- d Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences , University of Defence , Hradec Kralove , Czech Republic
| | - Jana Janockova
- e Biomedical Research Center , University Hospital Hradec Kralove , Hradec Kralove , Czech Republic
| | - Vendula Sepsova
- d Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences , University of Defence , Hradec Kralove , Czech Republic
| | - Ondrej Soukup
- e Biomedical Research Center , University Hospital Hradec Kralove , Hradec Kralove , Czech Republic
| | - Isabel Iriepa
- f Department of Organic Chemistry and Inorganic Chemistry, School of Biology, Environmental Sciences and Chemistry , University of Alcalá , Alcalá de Henares , Spain
| | - Ignacio Moraleda
- f Department of Organic Chemistry and Inorganic Chemistry, School of Biology, Environmental Sciences and Chemistry , University of Alcalá , Alcalá de Henares , Spain
| | - Emna Maalej
- g Laboratoire Matériaux, Traitement et Analyse (LMTA) , Institut National de Recherche et d'Analyse Physico-chimique Technopole , Ariana-Tunis , Tunisia
| | - M Carmo Carreiras
- h Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy , Universidade de Lisboa , Lisboa , Portugal
| | - Bernard Refouvelet
- b Laboratoire de Chimie Organique et Thérapeutique, Neurosciences Intégratives et Cliniques EA 481 , Univ. Bourgogne Franche-Comté , Besançon , France
| | - Fakher Chabchoub
- a Laboratory of Applied Chemistry, Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax , University of Sfax , Sfax , Tunisia
| | | | - Lhassane Ismaili
- b Laboratoire de Chimie Organique et Thérapeutique, Neurosciences Intégratives et Cliniques EA 481 , Univ. Bourgogne Franche-Comté , Besançon , France
| |
Collapse
|
11
|
Lajarín-Cuesta R, Arribas RL, Nanclares C, García-Frutos EM, Gandía L, de los Ríos C. Design and synthesis of multipotent 3-aminomethylindoles and 7-azaindoles with enhanced protein phosphatase 2A-activating profile and neuroprotection. Eur J Med Chem 2018; 157:294-309. [DOI: 10.1016/j.ejmech.2018.07.030] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Revised: 07/09/2018] [Accepted: 07/11/2018] [Indexed: 02/02/2023]
|
12
|
Yaghoubi A, Dekamin MG. Green and Facile Synthesis of 4H
-Pyran Scaffold Catalyzed by Pure Nano-Ordered Periodic Mesoporous Organosilica with Isocyanurate Framework (PMO-ICS). ChemistrySelect 2017. [DOI: 10.1002/slct.201700717] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Amene Yaghoubi
- Pharmaceutical and Heterocyclic Compounds Research Laboratory; Department of Chemistry; Iran University of Science and Technology; Tehran 16846-13114 Iran
| | - Mohammad G. Dekamin
- Pharmaceutical and Heterocyclic Compounds Research Laboratory; Department of Chemistry; Iran University of Science and Technology; Tehran 16846-13114 Iran
| |
Collapse
|
13
|
Mayank, Singh A, Kaur N, Singh N, Jang DO. A carbon quantum dot-encapsulated micellar reactor for the synthesis of chromene derivatives in water. MOLECULAR CATALYSIS 2017. [DOI: 10.1016/j.mcat.2017.06.032] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Advances toward multifunctional cholinesterase and β-amyloid aggregation inhibitors. Future Med Chem 2017; 9:1835-1854. [PMID: 28925729 DOI: 10.4155/fmc-2017-0094] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
The emergence of a multitarget design approach in the development of new potential anti-Alzheimer's disease agents has resulted in the discovery of many multifunctional compounds focusing on various targets. Among them the largest group comprises inhibitors of both cholinesterases, with additional anti-β-amyloid aggregation activity. This review describes recent advances in this research area and presents the most interesting compounds reported over a 2-year span (2015-2016). The majority of hybrids possess heterodimeric structures obtained by linking structurally active fragments interacting with different targets. Multipotent cholinesterase inhibitors with β-amyloid antiaggregating activity may additionally possess antioxidative, neuroprotective or metal-chelating properties or less common features such as anti-β-secretase or τ-antiaggregation activity.
Collapse
|
15
|
New (benz)imidazolopyridino tacrines as nonhepatotoxic, cholinesterase inhibitors for Alzheimer disease. Future Med Chem 2017; 9:723-729. [DOI: 10.4155/fmc-2017-0019] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Aim: Due to the multifactorial nature of Alzheimer’s disease, there is an urgent search for new more efficient, multitarget-directed drugs. Results: This paper describes the synthesis, antioxidant and in vitro biological evaluation of ten (benz)imidazopyridino tacrines (7–16), showing less toxicity than tacrine at high doses, and potent cholinesterase inhibitory capacity, in the low micromolar range. Among them, compound 10 is a nonhepatotoxic tacrine at 1000 mM, showing moderate, but totally selective electric eel acetylcholinesterase inhibition, whereas molecule 16 is twofold less toxic than tacrine at 1000 μM, showing moderate and almost equipotent inhibition for electric eel acetylcholinesterase and equine butyrylcholinesterase. Conclusion: (Benz)imidazopyridino tacrines (7–16) have been identified as a new and promising type of tacrines for the potential treatment of Alzheimer’s disease.
Collapse
|
16
|
Tetrahydropyranodiquinolin-8-amines as new, non hepatotoxic, antioxidant, and acetylcholinesterase inhibitors for Alzheimer's disease therapy. Eur J Med Chem 2017; 126:576-589. [DOI: 10.1016/j.ejmech.2016.11.050] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2016] [Revised: 11/21/2016] [Accepted: 11/22/2016] [Indexed: 11/21/2022]
|
17
|
Galimberti D, Scarpini E. Old and new acetylcholinesterase inhibitors for Alzheimer's disease. Expert Opin Investig Drugs 2016; 25:1181-7. [PMID: 27459153 DOI: 10.1080/13543784.2016.1216972] [Citation(s) in RCA: 70] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
INTRODUCTION To date, pharmacological treatment of Alzheimer's disease (AD) includes Acetylcholinesterase Inhibitors (AChEIs) for mild-to-moderate AD, and memantine for moderate-to-severe AD. AChEIs reversibly inhibit acetylcholinesterase (AChE), thus increasing the availability of acetylcholine in cholinergic synapses, enhancing cholinergic transmission. These drugs provide symptomatic short-term benefits, without clearly counteracting the progression of the disease. AREAS COVERED On the wake of successful clinical trials which lead to the marketing of AChEIs donepezil, rivastigmine and galantamine, many compounds with AChEI properties have been developed and tested mainly in Phase I-II clinical trials in the last twenty years. Here, we review clinical trials initiated and interrupted, and those ongoing so far. EXPERT OPINION Despite many clinical trials with novel AChEIs have been carried out after the registration of those currently used to treat mild to moderate AD, none so far has been successful in a Phase III trial and marketed. Alzheimer's disease is a complex multifactorial disorder, therefore therapy should likely address not only the cholinergic system but also additional neurotransmitters. Moreover, such treatments should be started in very mild phases of the disease, and preventive strategies addressed in elderly people.
Collapse
Affiliation(s)
- Daniela Galimberti
- a Neurology Unit, Department of Pathophysiology and Transplantation , University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico , Milan , Italy
| | - Elio Scarpini
- a Neurology Unit, Department of Pathophysiology and Transplantation , University of Milan, Fondazione Cà Granda, IRCCS Ospedale Maggiore Policlinico , Milan , Italy
| |
Collapse
|